Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01811199

Enrollment

100

Registered

2013-03-14

Start date

2011-02-28

Completion date

2013-05-31

Last updated

2013-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Thyroid Cancer

Keywords

Thyroid cancer, Breast cancer, Dexamethasone, Emesis

Brief summary

Hypothesis: Dexamethasone reduces postoperative emesis in thyroidectomy and mastectomy patients.

Detailed description

This study has been done to further study the effectiveness of dexamethasone in the prevention of postoperative emesis after breast and thyroid surgery and at the same time, the mechanism of action was investigated. In this prospective, randomized controlled trial it was hypothesized that corticosteroids exert their antiemetic effects in postoperative period via plasma prostaglandin F2 alpha (PGF2 α) and plasma leukotriene C4 (LTC4) inhibition.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* breast and thyroid cancer patients no neoadjuvant treated no NSAID or steroid usage heallthy volunteers, signed the informed consent

Exclusion criteria

* ones who did not sign the consent form NSAID or steroid users

Design outcomes

Primary

Measure	Time frame	Description
Number of participants will be evaluated to show effect of dexamethasone in reducing postoperative emesis	up to 3 days	participants will be followed for the duration of hospital stay, till they are discharged in avarage 3 days for postoperative emesis.

Countries

Turkey (Türkiye)

Outcome results